_256_384.jpg)
News | July 23, 2025
Cipla to invest in iCaltech to strengthen respiratory play
iCaltech is engaged in the design, development, and commercialisation of diagnostic medical equipment and apparatus
iCaltech is engaged in the design, development, and commercialisation of diagnostic medical equipment and apparatus
She was Group Chief Marketing Officer at CKA Birla Group in her last role
Upgrades 2025 full-year CDMO sales and margin outlook
Shelcal Total marks the brand’s evolution into a modern, consumer-focused nutrition portfolio
Reported EBITDA up by 19% year-on-year with reported EBITDA margin at 25%
Based on the CRL, the STARGLO data do not provide sufficient evidence to support the proposed second-line DLBCL indication in the US patient population
The phase III ARNASA study did not meet the primary endpoint of a statistically significant reduction in the AER at 52 weeks
During Q1FY26, the company incurred Capex of ~Rs. 48.5 crores mainly towards capacity expansion, backward integration and finished formulation R&D
Longer-term follow up in the FLAURA2 Phase III trial confirms the favourable benefit-risk profile of this combination
Clinical data showing unprecedented remission rates in newly diagnosed AML patients support advancing ICT01 into pivotal trials
Subscribe To Our Newsletter & Stay Updated
